| Literature DB >> 34196305 |
Andreas Goebel1,2, Emerson Krock3, Clive Gentry4, Mathilde R Israel4, Alexandra Jurczak3, Carlos Morado Urbina3, Katalin Sandor3, Nisha Vastani4, Margot Maurer4, Ulku Cuhadar4, Serena Sensi2, Yuki Nomura3, Joana Menezes3, Azar Baharpoor3, Louisa Brieskorn3, Angelica Sandström5, Jeanette Tour5, Diana Kadetoff5,6, Lisbet Haglund7, Eva Kosek5,8, Stuart Bevan4, Camilla I Svensson3, David A Andersson4.
Abstract
Fibromyalgia syndrome (FMS) is characterized by widespread pain and tenderness, and patients typically experience fatigue and emotional distress. The etiology and pathophysiology of fibromyalgia are not fully explained and there are no effective drug treatments. Here we show that IgG from FMS patients produced sensory hypersensitivity by sensitizing nociceptive neurons. Mice treated with IgG from FMS patients displayed increased sensitivity to noxious mechanical and cold stimulation, and nociceptive fibers in skin-nerve preparations from mice treated with FMS IgG displayed an increased responsiveness to cold and mechanical stimulation. These mice also displayed reduced locomotor activity, reduced paw grip strength, and a loss of intraepidermal innervation. In contrast, transfer of IgG-depleted serum from FMS patients or IgG from healthy control subjects had no effect. Patient IgG did not activate naive sensory neurons directly. IgG from FMS patients labeled satellite glial cells and neurons in vivo and in vitro, as well as myelinated fiber tracts and a small number of macrophages and endothelial cells in mouse dorsal root ganglia (DRG), but no cells in the spinal cord. Furthermore, FMS IgG bound to human DRG. Our results demonstrate that IgG from FMS patients produces painful sensory hypersensitivities by sensitizing peripheral nociceptive afferents and suggest that therapies reducing patient IgG titers may be effective for fibromyalgia.Entities:
Keywords: Autoimmune diseases; Neurological disorders; Neuroscience; Pain
Year: 2021 PMID: 34196305 DOI: 10.1172/JCI144201
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808